Addus HomeCare (ADUS) Stock Forecast & Price Target

Addus HomeCare is viewed positively because its core Personal Care business is delivering solid organic growth, with 1Q26 same-store revenue up 6.5%, billable hours up 5.2%, and adjusted EBITDA of $44.5 million slightly above Street expectations despite lighter revenue. The company also appears well positioned to accelerate growth through M&A, given its $103 million of cash, $94 million of total debt, and expected 2026 EBITDA and FCF of $196 million and $120 million, respectively, which support larger acquisitions than the $32 million spent in 2025. Additional optimism comes from rate improvements in key markets, favorable federal and state regulatory conditions, and new Indiana personal care acquisitions that expand its footprint in a state with a favorable managed Medicaid mix.

Addus HomeCare is facing a negative fundamental outlook because its core Personal Care business is exposed to Medicaid policy risk, including a probable repeal of the 80/20 Medicaid Access rule and possible state rate cuts or wage increases without offsetting reimbursement, which could compress margins where service margins exceed 20%. The company also faces meaningful uncertainty from more than 20% of revenue tied to the Illinois CCP, while hospice and home health remain vulnerable to reimbursement pressure, labor constraints, and scrutiny after the May 13 six-month Medicare moratoria. Although 1Q26 revenue rose 7.7% to $363.6 million and EBITDA reached $44.5 million, hospice revenue missed expectations at $66 million and home health revenue fell to $16.7 million, underscoring slowing momentum beneath still-firm topline growth.